NCT03072953View on ClinicalTrials.gov

Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

June 7, 2017

Primary Completion Date

May 22, 2018

Study Completion Date

May 22, 2018

Conditions
Pyoderma Gangrenosum
Interventions
DRUG

APD334

APD334 active treatment

Trial Locations (6)

2145

Westmead Hospital, Westmead

3050

Royal Melbourne Hospital, Parkville

3128

Eastern Clinical Research Unit, Box Hill

4102

Veracity Clinical Research, Woolloongabba

6160

Fremantle Dermatology, Fremantle

Unknown

Braemar Day Hospital, Hamilton

Sponsors
All Listed Sponsors
lead

Arena Pharmaceuticals

INDUSTRY

NCT03072953 - Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum | Biotech Hunter | Biotech Hunter